Want to see HK:6826 full AI Analyst Report?
6826 Stock Chart & Stats
HK$24.90
-HK$0.40(-1.57%)
At close: 4:00 PM EST
HK$24.90
-HK$0.40(-1.57%)
Day’s Range― - ―
52-Week RangeHK$15.04 - HK$30.68
Previous CloseN/A
Volume220.22K
Average Volume (3M)127.96K
Market Cap
HK$7.09B
Enterprise ValueHK$1.36K
Total Cash (Recent Filing)HK$2.40B
Total Debt (Recent Filing)HK$443.14M
Price to Earnings (P/E)44.6
Beta0.85
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.13%
Share Statistics
EPS (TTM)0.63
Shares Outstanding34,780,340
10 Day Avg. Volume92,888
30 Day Avg. Volume127,956
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)0.94
Price to Sales (P/S)2.08
P/FCF Ratio11.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.6
Revenue Forecast (FY)HK$2.61B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low and stable leverage limits financial risk and preserves flexibility to fund research, capacity, or commercialization during a softer earnings period. The large equity base also provides resilience against operating volatility.
Diversified Healthcare PortfolioExposure to multiple healthcare applications reduces dependence on a single product category. Ophthalmic procedures, aesthetic treatments, and tissue-repair needs provide several avenues for recurring demand, distribution expansion, and product innovation.
Positive Cash GenerationPositive operating and free cash flow indicates the company can still support operations and investment internally rather than relying heavily on external financing. This strengthens resilience despite weaker recent earnings and uneven cash conversion.
Bears Say
Revenue ContractionRecent top-line contraction suggests weaker demand, product mix, or competitive conditions across the portfolio. Sustained revenue softness could constrain operating leverage, reduce resources for innovation, and make a return to prior profitability levels more difficult.
Margin And Earnings PressureThe sharp margin reset indicates that historical profitability may not be fully sustainable under current conditions. Lower operating efficiency reduces earnings resilience and leaves less capacity to absorb pricing pressure, procurement changes, or higher commercialization costs.
Volatile Cash ConversionPositive cash flow is weakened by declining conversion and a history of swings linked to investment or working-capital needs. This can make internally funded growth less predictable and may limit the company’s ability to consistently support expansion or distributions.
Shanghai Haohai Biological Technology Co., Ltd. Class H News
6826 FAQ
What was Shanghai Haohai Biological Technology Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Haohai Biological Technology Co., Ltd. Class H lowest stock price was HK$15.04 and its highest was HK$30.68 in the past 12 months.
What is Shanghai Haohai Biological Technology Co., Ltd. Class H’s market cap?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s market cap is HK$7.09B.
When is Shanghai Haohai Biological Technology Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s upcoming earnings report date is Oct 23, 2026 which is in 31 days.
How were Shanghai Haohai Biological Technology Co., Ltd. Class H’s earnings last quarter?
Shanghai Haohai Biological Technology Co., Ltd. Class H released its earnings results on Aug 21, 2026. The company reported HK$0.574 earnings per share for the quarter.
Is Shanghai Haohai Biological Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Haohai Biological Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Haohai Biological Technology Co., Ltd. Class H pay dividends?
Shanghai Haohai Biological Technology Co., Ltd. Class H pays a Semiannually dividend of HK$0.289 which represents an annual dividend yield of 6.13%. See more information on Shanghai Haohai Biological Technology Co., Ltd. Class H dividends here
What is Shanghai Haohai Biological Technology Co., Ltd. Class H’s EPS estimate?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Haohai Biological Technology Co., Ltd. Class H have?
Shanghai Haohai Biological Technology Co., Ltd. Class H has 34,780,340 shares outstanding.
What happened to Shanghai Haohai Biological Technology Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Haohai Biological Technology Co., Ltd. Class H reported an EPS of HK$0.574 in its last earnings report. Following the earnings report the stock price went down -0.123%.
Which hedge fund is a major shareholder of Shanghai Haohai Biological Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6826
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Haohai Biological Technology Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.70%
12-Months-Change
Fundamentals
Return on Equity
6.13%
Trailing 12-Months
Asset Growth
-3.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and commercialization of biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various other international regions. A comprehensive product portfolio addresses several key medical disciplines. Within ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. Orthopedics products encompass sodium hyaluronate injections and medical chitosan. For wound repair, it manufactures recombinant human epidermal growth factor, effective in treating burn wounds, residual wounds, donor site post-traumatic wounds, and both fresh and chronic ulcerations. Additionally, the company develops anti-adhesion materials, including medical sodium hyaluronate gel and medical chitosan, as well as hemostatic solutions such as collagen sponges and porcine fibrin sealants. Beyond its therapeutic offerings, Shanghai Haohai maintains a significant presence in the medical aesthetics market. This segment features a range of hyaluronic acid (HA) dermal fillers: Matrifill, positioned as a first-generation mono-phase injectable HA gel; Janlane, a second-generation filler engineered for dynamic application; and Hyalumatrix, a third-generation product providing precise aesthetic embellishment. Its aesthetic portfolio is further complemented by radio frequency devices and laser equipment. Furthermore, the company actively engages in the research and development of biological engineering and pharmaceutical products, extending services such as technology transfer and consultation. It also conducts investment and trading operations. Established in 2007, the entity initially traded as Haohai Limited before officially adopting the name Shanghai Haohai Biological Technology Co., Ltd. in 2010. Its corporate headquarters are based in Shanghai, China.
Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) Earnings & Revenues
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―